| A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma J Groot, M Ott, J Wei, C Kassab, D Fang, H Najem, B O’Brien, ... CNS oncology 11 (2), CNS87, 2022 | 48 | 2022 |
| Intratumoral delivery of STING agonist results in clinical responses in canine glioblastoma CE Boudreau, H Najem, M Ott, C Horbinski, D Fang, CM DeRay, ... Clinical Cancer Research 27 (20), 5528-5535, 2021 | 38 | 2021 |
| New approaches to glioblastoma M Khasraw, Y Fujita, C Lee-Chang, IV Balyasnikova, H Najem, ... Annual review of medicine 73 (1), 279-292, 2022 | 27 | 2022 |
| Macrophage–endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa X Ren, LD Manzanares, EB Piccolo, JM Urbanczyk, DP Sullivan, ... The Journal of clinical investigation 133 (15), 2023 | 25 | 2023 |
| The eclectic nature of glioma-infiltrating macrophages and microglia VA Arrieta, H Najem, E Petrosyan, C Lee-Chang, P Chen, AM Sonabend, ... International journal of molecular sciences 22 (24), 13382, 2021 | 20 | 2021 |
| Immune microenvironment landscape in CNS tumors and role in responses to immunotherapy H Najem, M Khasraw, AB Heimberger Cells 10 (8), 2032, 2021 | 16 | 2021 |
| Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution CHG Lucas, K Mirchia, K Seo, H Najem, WC Chen, N Zakimi, K Foster, ... Nature genetics 56 (6), 1121-1133, 2024 | 13 | 2024 |
| Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression H Najem, M Ott, C Kassab, A Rao, G Rao, A Marisetty, AM Sonabend, ... JCI insight 7 (9), e157612, 2022 | 12 | 2022 |
| The use of targeted cytokines as cancer therapeutics in glioblastoma M Sooreshjani, S Tripathi, C Dussold, H Najem, J de Groot, RV Lukas, ... Cancers 15 (14), 3739, 2023 | 11 | 2023 |
| Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas MW Youngblood, Z Erson-Omay, C Li, H Najem, S Coșkun, E Tyrtova, ... Nature communications 14 (1), 6279, 2023 | 10 | 2023 |
| cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma S Tripathi, H Najem, AS Mahajan, P Zhang, JT Low, AH Stegh, MA Curran, ... F1000Research 11, 1010, 2022 | 9 | 2022 |
| Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system J Wei, R Song, A Sabbagh, A Marisetty, N Shukla, D Fang, H Najem, M Ott, ... Oncoimmunology 11 (1), 2062827, 2022 | 8 | 2022 |
| STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma H Najem, ST Lea, S Tripathi, L Hurley, CH Chen, I William, M Sooreshjani, ... Journal of Clinical Investigation 134 (12), e175033, 2024 | 7 | 2024 |
| Cancer-associated fibroblast–secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas S Tripathi, H Najem, C Dussold, S Pacheco, J Miska, K McCortney, ... The Journal of clinical investigation 134 (4), 2024 | 7 | 2024 |
| Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution CH Lucas, K Mirchia, K Seo, H Najem, W Chen, N Zakimi, A Choudhury, ... Research Square, rs. 3. rs-2921804, 2023 | 7 | 2023 |
| Myeloid cell classification and therapeutic opportunities within the glioblastoma tumor microenvironment in the single cell-omics era CJ Larkin, VA Arrieta, H Najem, G Li, P Zhang, J Miska, P Chen, ... Frontiers in immunology 13, 907605, 2022 | 7 | 2022 |
| Clinical management of supratentorial non-skull base meningiomas A Adekanmbi, MW Youngblood, CL Karras, EA Oyetunji, J Kalapurakal, ... Cancers 14 (23), 5887, 2022 | 7 | 2022 |
| CD11c+ CD163+ Cells and signal transducer and activator of transcription 3 (STAT3) expression are common in melanoma leptomeningeal disease H Najem, A Marisetty, C Horbinski, J Long, JT Huse, IC Glitza Oliva, ... Frontiers in immunology 12, 745893, 2021 | 7 | 2021 |
| NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy A Choudhury, MA Cady, CHG Lucas, H Najem, JJ Phillips, B Palikuqi, ... bioRxiv, 2023 | 6 | 2023 |
| Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: a novel combinatorial immunotherapy regimen for gliomas KS Kim, K Habashy, A Gould, J Zhao, H Najem, C Amidei, R Saganty, ... Neuro-oncology 26 (11), 2044-2060, 2024 | 5 | 2024 |